PT - JOURNAL ARTICLE AU - René, Staritzbichler AU - Pascal, Hunold AU - Irina, Estrela-Lopis AU - Hildebrand, Peter W. AU - Berend, Isermann AU - Thorsten, Kaiser TI - Raman spectroscopy on blood serum samples of patients with end-stage liver disease AID - 10.1101/2021.06.06.21258433 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.06.21258433 4099 - http://medrxiv.org/content/early/2021/07/23/2021.06.06.21258433.short 4100 - http://medrxiv.org/content/early/2021/07/23/2021.06.06.21258433.full AB - Raman spectroscopy has shown to be a promising method for the examination of biomedical samples. However, until now, its efficacy has not been established in clinical diagnostics. In this study, Raman spectroscopy’s potential application in medical laboratories is evaluated for a large variety (38) of biomarkers. Given 234 serum samples from a cohort of patients with different stages of liver disease, we performed Raman spectroscopy at 780nm excitation wavelength. The Raman spectra were analyzed in combination with the results of routine diagnostics using specifically developed complex mathematical algorithms, including fluorescence filtering, frequency subset selection and several overfitting circumventing strategies, such as independent validation. With the results of this cohort, which were validated in 328 independent samples, a significant proof-of-concept study was completed. This study highlights the need to prevent overfitting and to use independent data for validation. The results reveal that Raman spectroscopy has high potential for use in medical laboratory diagnostics to simultaneously quantify multiple biomarkers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We selected 234 blood serum samples from well-characterized patients suffering from liver disease. Only residual serum samples from routine diagnostics were retrospectively used. The ethics committee of the University Hospital Leipzig approved the use of residual serum samples and pseudonymized patient data for this study without informed consent (ethical approval 039-14). Accordingly, an additional requirement for informed consent of the patients was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is included in the manuscript and supplementary material.